It has been known for many years that drugs given to pregnant women for therapeutic purposes can pass through the placental barrier and produce various effects on the developing embryo. The passage of drugs through the placenta is well
manifesting itself through a final common path and, on the other, of regarding each teratogenic agent as having its own idiosyncratic pattern of effect on the enzymatic processes of the cell, we would hold an intermediate view, inclining more to the former. Our experience suggests that there are probably a small number ofpathwaysbywhich malformations are produced. We do not, indeed, totally exclude the possibility that there may be a single final cause as, for example, interference with carbohydrate metabolism or production of temporary anoxia. We would see, these final pathways as responsible for the broad pattern of malformations, while the detailed variations would be attributable to a number of genetic and environmental factors. Of these factors unquestionably the most important is the maternal and feetal genotype with all the implications of interand intra-species differences in response to teratogenic agents which this implies. We would, nevertheless, regard the environmental factors as more important in regulating the response of the embryo to teratogenic agents than might those who have approached the subject from genetics and experimental embryology where the great advances have been made in the study of submammalian forms. Only during the short period between fertilization and the embedding of the blastocyst does the situation of the mammalian embryo resemble that of the embryo of lower forms. It is worth repeating that it is precisely during this period that teratogenic agents do not work as such: they kill, but they do not maim the embryo. In the development of insects, nonviviparous fishes, amphibians and birds, from the study of which so many of our basic genetic and embryological concepts have been formulated, the maternal contribution after fertilization is restricted to the provision of, at most, physical protection and warmth. In the mammal where the foetus receives so much more directly from the mother -the minerals and amino acids needed for growth, the glucose and oxygen needed to maintain the existing tissues -it is obvious that the mother as a whole, her age, size, physical fitness, previous reproductive history, nutritional standdards and hormonal levels may be of vital importance in serving to modify the response of the embryo to a teratogenic agent.
From the concepts of teratogenic activity outlined above we have reached the following conclusions on the testing of new drugs for teratogenic activity on the mammalian embryo. For comparisons between tests carried out in different institutions or in the same institution at different times, a rigorous protocol must be adopted. It is not only necessary to use animals of as nearly as possible identical heredity for experimental and control groups, it is also obligatory to use animals of standard size, weight and previous reproductive performance, fed, watered an.d exposed to sunlight and warmth at a predetermined level. In addition, there should be an agreed time of day for the administration of drugs to be tested. Even with the strictest adherence to this procedure, we believe that no drug should finally be regarded as safe, or condemned as noxious, for the human embryo, on the basis of animal experiments alone. We must stress, however, that experimental mammaLian teratology itself is yet hardly in its infancy, even though the blastocyst was embedded as it were by Hale as long as thirty years ago. So far we have seen the contributions made by a few observers working in a variety of disciplines at schools scattered widely over the globe on a subject, the lack of financial support for which indicated its insignificance in practical affairs. Now that the vast resources of the drug industry and of private and nationalized medicine are to be poured into research in this field, our tentative conclusions may relate in some way to the fundamental principles that must shortly be revealed. Here we have for once a problem in the solution ofwhich pure and applied science will both equally rejoice and equally benefit, for the drug industry will hardly be able to learn how to test its products adequately without finding out in the process much that embryologists have been wanting to know for a long time.
Section ofExperimental Medicine and Therapeutics 601 reviewed by Hagerman & Villee (1960) . A more general review of the passage of drugs across body membranes, including the placenta, is given by Schanker (1962) . It has also been known that the foetus may be particularly susceptible to the pharmacological actions of certain drugs, the classical example being morphine. What has not been realized until fairly recently is that drugs which are comparatively well tolerated by the maternal organism can be highly toxic to the foetus at certain stages of embryogenesis leading either to its death or to the production of abnormalities, or both, though the relation between these two effects has not been clearly worked out. Our knowledge of certain aspects of this question is very incomplete, and much more work is required to elucidate the relationship between an effect produced experimentally by drugs in ammals, and the possible actions of such drugs in man. In this respect the toxicology of the foetus is merely one aspect, though an important one, of general toxicology, where the question of the relation of toxic effects in animals and in man needs so much further clarification.
It is worth outlining the various mechanisms by which the foetus can suffer deleterious effects during pregnancy, because such knowledge might help us to prevent their occurrence. These mechanisms might be classified under the following headings:
(1) Toxic effects exerted directly on the foetus, and of significance because: (a) The foetus as a. whiole is much more sensitive than the adult to a particular drug; a therapeutic dose given to the mother might therefore be toxic and even lethal to the feetus. A similar relationship may hold for absence of some essential metabolite, e.g. a vitamin.
(b) The developing foetus is particularly sensitive at certain stages of development to the action of a drug. This may cause death of the feetus or abnormal development. It should be stressed that drugs which cause congenital abnormalities frequently also produce death of the foetus with consequent resorption or abortion, but that we do not know whether drugs which cause resorption experimentally are necessarily teratogenic.
(2) Toxic effects exerted on the functional activity of the placenta: It is obvious that this may affect the feetus and may occur in a variety of clinical conditions, notably pre-eclamptic toxemia. There may also be more subtle pharmacological effects which I shall mention, though their clinical implications are at present a matter of inference.
(3) Effects of drugs exerted primarily on the maternal organism but which secondarily involve the foetus: Such effects may broadly be classed under two headings: (a) Effects on the hormonal mechanism involved in the maintenance of pregnancy. (b) Effects on the nutrition of the maternal organism brought about by actual deprivation of nutrient substances or in a variety of other ways, e.g. interference with adrenal cortical function.
It is well to realize that the above classification is to some extent theoretical, for we do not know the exact site of action of quite a number of drugs which are toxic to the feetus.
Direct Toxic Effect ofDrugs on the Embryo This has always been of therapeutic importance and has always needed consideration when a drug was used at any stage of pregnancy. The question has acquired special significance in recent years because a deliberate search has been made for substances which might have a specific action in the control of conception. Such drugs might have an action on the young embryo to produce interruption of pregnancy, and it was realized that unless this effect was reliably produced in 100% of cases, there was a danger of the survival of a partially damaged feetus, and thus the danger of foetal abnormalities. The concept of a therapeutic ratio in this connexion was developed by Robson in 1959. This was based on work done with nucleotoxic substances, which had been found to have a direct lethal action on the feetus. The therapeutic ratio was here broadly defined as the ratio between the dose lethal to the mother and that lethal to the foetus and it was urged that if the ratio was high enough, the danger of the survival of a damaged foetus would become very small. One ofthe nucleotoxic substances described, DON (6-diazo-5-oxo-norleucine) had a therapeutic ratio of the order of 150 in mice (Thiersch 1957) while another, azaserine, had a therapeutic ratio of about 40 in rats (Murphy & Karnofsky 1956) . By that time it had already been found that another of these drugs, the folic acid antagonist aminopterin, though toxic to the feetus both experimentally and clinically, was liable under both circumstances also to damage a surviving foetus, thus causing congenital abnormalities (see Murphy 1960 (Somers 1962 , Giroud et al. 1962 ), mice (Giroud et al. 1962) , rats of certain strains (King & Kendrick 1962 , Rignami et al. 1962 ) and chicks (injection into the (Bel et al. 1962) . It is possible that the tetatogenic effects of thalidomide are not produced by the drug itself but by a metabolic product, of which there are a number (Faigle et al. 1962) . The different susceptibilities of various animal species to the teratogenic action of the drug may be related to different metabolic paths in different species, and this needs further investigation.
Two other drugs illustrate the fact that substances commonly taken by man and not so far suspected of being teratogenic, even though in use overmany years, can nevertheless produce damage to the fetus in experimental animals, provided the dose is high enough. The most striking one is sodium salicylate. This was given to pregnant rats (days 9-11) in doses which caused the death of some of the mothers, i.e. 300-900 mg/kg which compared with the LD 50 in rats of about 1,500 mg/kg. In rats so treated there were many fetal abnormalities and also many resorptions. Similar results have also been obtained with methyl salicylate (Warkany & Takacs 1959) .
Doses of sodium salicylate up to 200 mg/kg have been recommended for the treatment of rheumatic fever, so that there is a narrow margn between the doses, expressed per unit of body weight, which are respectively teratogenic in animals and used clinically in human disease.
Equally marked were the results obtained with nicotine, a drug inhaled by many pregnant mothers. Given to mice in a dose of 25 mg/kg particularly on days 9-11 ofpregnancy, there were many abnormalities and also many resorptions. In fact in many cases the embryos were dead very soon after injection of the drug (Nishimura & Nakai 1958) . Again this dose is high and quite near the toxic level, the LD 50 in rats being 35 mg/kg (Behrendt & Thienes 1933) , though the authors who investigated the teratogenic effect do not state whether any toxic effects were produced in the injected mice (apart from the effects on pregnancy). These teratogenic doses of nicotine are of course much higher than are likely to be inhaled even by a chain smoker.
It can thus be concluded that some drugs which have not been implicated in the production of fetal abnormalities in man -and it is highly unlikely that such a relationship would not have been observed -can nevertheless quite frequently produce abnormalities in animals when -given in toxic doses. It must also be emphasized that the Section ofExperimental Medicine and 7herapeutics 603 Kalter & Warkany (1961) teratogenic dose of sodium salicylate is of the same order as the dose used clinically in man.
We have recently investigated the effect of imipramine in rabbits because of the finding that it interrupted pregnancy in mice (Robson & Sullivan 1963a) . It proved much less potent in this respect in rabbits but nevertheless produced some striking abnormalities, as well as some resorptions. The doses used were of the order of 15 mg/kg given from the 1st to the 15th day of pregnancy, i.e. as in the other experiments, including that stage of embryogenesis when interference might lead to the development of abnormalities in surviving fetuses. These doses produced no obvious toxic effects in the mothers. Moreover on a weight-for-weight basis they are not so much greater than the doses used clinically in man, sometimes over fairly long periods. So far there have been no reports of congenital abnormalities being produced by imipramine in man. only by a direct toxic action, but also by interfering with placental function. We were led to this conclusion by experiments on the effect of 5-hydroxytryptamine (5-HT) on pregnancy. It was found that the subcutaneous injection of a single dose of this drug into mice very rapidly led to death of the foetuses, sometimes within less than half an hour. At that time the placenta was usually normal, even microscopically, though within twenty-four hours degenerative changes occurred, sometimes accompanied by gross hemorrhage into the placenta (Poulson et al. 1960 ). In the animals used, the drug had no acute direct toxic action on the fotus, as was shown by injecting it into the embryo in situ: the concentration of 5-HT so produced was much higher than that resulting from its injection into the mother and yet no harmful effect resulted from its intra-embryonic injection (Robson & Sullivan 1963b ).
These results led us to investigate the effect of the drug on the blood supply to the placenta and on the functional activity of the organ. This was done using respectively radiochromium-labelled red cells and radioactive sodium (Robson & Sullivan 1963b ).
When labelled mouse red cells were injected intravenously into pregnant mice they rapidly entered the placenta so that after two minutes their concentration in the placental maternal blood was as high as in the mixed venous maternal blood. Thus mixing of the maternal and placental blood occurred very rapidly. However, when the labelled cells were injected into the mother five minutes after the subcutaneous administration of 5-HT, the mixing of these bloods was delayed for about twenty minutes. When 5-HT was given to animals half an hour after the administration of labelled cells, i.e. after complete mixing of maternal and placental blood had occurred, then the radioactivity of the placenta was not diminished. It must therefore be concluded that 5-HT causes contraction of the blood vessels supplying the placenta, though it does not constrict the maternal placen'tal vessels. Though this decrease in the blood supply of the placenta (and foetus) is fairly brief, it might nevertheless harm the foetus.
The findings with radiosodium are equally interesting. When this is given intravenously to pregnant mothers it rapidly enters the placenta and feetus and it is quite possible, as Huggett (1959) has maintained, that an active transport mechanism is involved. When 5-HT is given before the injection of labelled sodium, the entry of the sodium into the placenta and foetus is greatly delayed. After half an hour there is little in the placenta, and practically none in the fcetus. Though much further work along these lines remains to be done, the results suggest that 5-HT has a specific effect on some transport processes in the placenta. These effects of 5-HT on placental blood supply and placental transport can rapidly kill the foetus. We are at present investigating what happens when the action of 5-HT is less drastic and the foetuses survive its action. Since fctal abnormalities can occur following deprivation of some essential substances as well as following hypoxia (Kalter & Warkany 1959 , Ingalls 1960 , it may be that even the transient effect of a drug like 5-HT could lead to malformation of the foetus. That this is not entirely speculative is shown by our preliminary results that in pre-eclamptic toxemia and in some cases of hypertension, the 5-HT content of the placenta is much higher than normal. We have also one experimental result to date. Seven mice on the 12th day of pregnancy (counting the finding of the vaginal plug as day 1) received a subcutaneous injection of 1 mg of 5-HT creatinine sulphate. In all but one this interrupted the pregnancy and at post-mortem on day 19 the uterus contained only placenta and hemorrhagic foetal remains. In one animal five live fcetuses were found in the uterus (as well as three resorptions) and two of the live animals showed abnormalities. In one the left forelimb had abnormal digits; similar changes were less marked in the right forelimb. Another foetus showed an abnormality in the left forelimb only. We have since then obtained many abnormalities in mice by the injection of 5-HT during pregnancy.
Very recently relevant work has been referred to in Medical News (March 9, 1963 ). It appears that investigators at the University of California have produced experimental abnormalities in animals with 5-HT, and they also refer to a woman with carcinoid syndrome (in which large amounts of 5-HT are produced) who gave birth to children with gross defects in four pregnancies.
Effect on the Maternal Organism That illness of the mother, e.g. diabetes, may have deleterious repercussions in the foetus has been known for a long time. In recent-years the more specific action of rubella has been extensively investigated.
Experimentally it has been clearly shown that interruptions of pregnancy, at least during its early stage, can result-from the action of drugs which affect the hormonal mechanism necessary for its maintenance. This includes not only effects on the young embryo but also prevention -of implantation. If I refer particularly to the action in this respect of iproniazid and other amine oxidase inhibitors, it is because we have studied them in some detail. Some of these drugs are highly active in doses which have no obvious toxic effects on the maternal organism. These actions appear to be due to an inhibition of the pituitary, since they can be reversed by the administration of anterior pituitary luteotrophic hormone, and by progesterone (Poulson & Robson 1963) . Occasionally the effect of such a drug is incomplete and some foetuses survive. Whether such treatment can produce foetal abnormalities has not yet been studied. This question is, however, important since similar effects on pregnancy have been obtained with a number of drugs acting on the central nervous system (West 1962 , and our own observations), and the clinical use of such drugs is ever increasing.
The interferences which may affect pregnancy and produce abnormalities by some general action on the mother include deprivation of a variety of hormones and other essential metabolites, including oxygen, the action being brought about by specific withdrawal of a substance from the food or by fasting, a subject well reviewed by Kalter & Warkany (1959) . What we do not usually know is whether these deficiencies affect the fcetus through a general interference with metabolic activities of the maternal organism or whether the deprivations directly affect the feetuses. A particularly interesting aspect of this is the production of congenital malformations and also of many resorptions in guinea-pigs by adrenalectomy (Hoar & Salem 1962 (1) Some drugs which have produced teratogenic effects in animals are also similarly toxic to the human feetus (e.g. thalidomide, aminopterin).
(2) Some drugs which are widely used in man are teratogenic in anials when given in doses which are toxic to the mother animal (e.g. sodium salicylate, nicotine).
(3) Some drugs widely used in man are teratogenic in animals in doses non-toxic to the mother animal (e.g. imipramine, cortisone).
(4) Drugs can be teratogenic in animals in the same range of doses (on a weight-for-weight basis) as are used clinically in man (e.g. sodium salicylate, imipramine).
These results must be viewed in the light of our general knowledge of toxicology. When we test a drug in animals for its potential toxicity it is important that we should deliberately try to include a high dose which will produce some toxic effects. The occurrence of such toxic effects with the high dose does not necessarilycontraindicate the clinical use of the drug.
The following suggestions are offered very tentatively, since I am very conscious that our knowledge of the subject is imperfect and that further knowledge, which may become available very quickly, may invalidate some of them. I will nevertheless hazard the following:
(1) When drugs produce teratogenic effects in animals in doses which also produce toxic effects in the mother, i.e. when the therapeutic ratio is low, it should not be regarded as serious. Such a therapeutic ratio may be different in different animal species. Any new drug will have to be tested in several species before its introduction into clinical medicine and we should be reasonably satisfied when the dose which produces a teratogenic effect in any species tested is also toxic to the maternal organism in that species.
(2) When drugs produce teratogenic effects in doses which are not toxic to the mother, it must be considered much more significant. Moreover, the greater the therapeutic ratio (i.e. the greater the ratio between the dose toxic to the animal mother and that which produces teratogenic effects in the feotuses), the more will we hesitate to use the drug clinically in women.
(3) In assessing the possible use of a new drug in man we should take into account the clinical indication for the drug. If it may be life-saving we will accept a greater risk of possible teratogenic effect than if the clinical indication is less important.
.
(4) When any drug already in clinical use is shown to be teratogenic in anima tests, extensive investigations should be made to detect whether any damage to the feetus has in fact been produced in patients who have taken the drug.
